Business
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025 IND clearance received from U.S. FDA for novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004, paving way for mid-year clinical program initiation; Company to host webcast focused on ALX2004 research program on May 20Company will not pursue U.S. registrational
About this update from Alx Oncology Holdings Inc.
[{"type":"image","alt":"ALX Oncology","displaySize":"","headline":null,"caption":"ALX Oncology","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":195,"url":"https://media.zenfs.com/en/globenewswire.com/470f956a3deddaf81b04c64bb1806e3d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tBYkx9_bHbgV6zgiof22Rw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/470f956a3deddaf81b04c64bb1806e3d","width":300,"height":195}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025","length":236,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":236,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"IND clearance received from U.S. FDA for novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004, paving way for mid-year clinical program initiation; Company to host webcast focused on ALX2004 research program on May 20","length":223,"tagName":"p"}]},{"val":[{"type":"text","content":"Company will not pursue U.S. registrational path in gastric cancer following receipt of FDA feedback that accelerated approval pathway is not feasible based on ASPEN-06 due to standard-of-care evolving to ENHERTU®","length":213,"tagName":"p"}]},{"val":[{"type":"text","content":"Data milestones expected across Company’s three clinical programs in 2026","length":73,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash runway has been extended into Q4 2026","length":42,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":551,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.","length":387,"tagName":"p"},{"type":"text","content":"“In the first quarter of the year, we focused our development strategy for evorpacept on the anti-cancer antibody comb...